Skip to content
GLP-1 Decoder

GLP-1 Before and After: Real Results by Month (Photos and Data)

In SURMOUNT-1, people on tirzepatide 15 mg weekly lost 20.9% of their body weight on average over 72 weeks, against 3.1% on placebo.

Average loss, top dose
20.9%
On placebo
3.1%
Trial length
72 weeks
Trial
SURMOUNT-1

Weight loss and half-life overview

How long each medicine stays in your body
Wegovy7 dOzempic7 dRybelsus7 dZepbound5.5 dMounjaro5 dTrulicity5 dFoundayo1.6 dSaxenda0.5 dVictoza0.5 dByetta0.1 d

Half-life in days means how long your body takes to clear half a dose, based on section 12.3 of each FDA label.

Weight loss from each medicine's main weight trial
Zepbound20.9%Wegovy14.9%Foundayo11.1%Saxenda7.4%

Percentage of body weight. The trials, doses, and lengths varied, so compare each result with its own placebo on its page.

Sources (10)

FDA label (DailyMed) 1 2 3 4 5 6 7 8 9 10.

First, the GLP-1 numbers before and after

Each GLP-1 is shown at its highest dose tested in the main weight trial. Different trials enrolled different people.

Average weight loss in each trial by dose group
TrialDose groupAverage weight lostPlacebo or comparisonWeeksWho was in it
STEP 1Semaglutide 2.4 mg weekly14.9%2.4%68Adults with obesity or overweight, without diabetes
OASIS 4Wegovy pill 25 mg daily13.6%2.4%64Adults with obesity or overweight, without diabetes
SURMOUNT-1Tirzepatide 15 mg weekly20.9%3.1%72Adults with obesity or overweight, without diabetes
SURMOUNT-2Tirzepatide 15 mg weekly14.7%3.2%72Adults with obesity or overweight but no type 2 diabetes
SCALE Obesity and PrediabetesLiraglutide 3.0 mg daily7.4%3%56Adults with obesity or overweight who also have type 2 diabetes
ATTAIN-1Foundayo 17.2 mg daily11.1%2.1%72Adults with obesity or overweight, without diabetes
ATTAIN-2Foundayo 17.2 mg daily9.6%2.5%72Adults with obesity or overweight but no type 2 diabetes
STEP 2Semaglutide 2.4 mg weekly9.6%3.4%68Adults with obesity or overweight but no type 2 diabetes

Sources: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed).

First, the GLP-1 numbers before and after

The trial average of 20.9% was applied to three starting weights. Simple math only, not a prediction for one person: some lose more, while others lose less.

Average pounds lost on GLP-1 medicines
Starting weightAverage loss on tirzepatide 15 mg weeklyAverage loss on placebo
180 lbabout 38 lbabout 6 lb
220 lbabout 46 lbabout 7 lb
260 lbabout 54 lbabout 8 lb

Sources: FDA label (DailyMed).

Week-by-week view

Section sources: health.clevelandclinic.org, DailyMed FDA label.

What makes it stall, and what helps

  1. See where you are in the dose steps. Lower doses led to less weight loss in every trial listed above.
  2. Over the last month, count the doses you missed or took late.
  3. For a few days, record your food and drink. Calories add up from drinks and grazing as your portions get smaller.
  4. Talk with your prescriber about thyroid testing or blood sugar testing. If your progress has stayed flat for months, also discuss changing medicines.

Every living with it page